Brought to you by:
Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy
Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results from the RANGER II SFA randomized controlled trial have demonstrated, investigators revealed during a late-breaking session…
VIVA 2021: Consensus established for appropriate use of IVUS in peripheral interventions
A worldwide committee of 40 cross-specialty medical experts achieved what was hailed as the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease (PVD) interventions. Global experts conducted a systematic and comprehensive review of key…
Save the date for new PAD skills workshop
September is National PAD Awareness Month, and the Society for Vascular Surgery (SVS) will spend the month not only calling attention to causes and treatment for the disease, but also planning a peripheral arterial disease (PAD) skills workshop. The hands-on…
First patient enrolled in BIONETIC-I study of iliac artery treatment
Biotronik has announced the first patient enrollment in the BIONETIC-I study of the safety and efficacy of the Dynetic-35 cobalt chromium balloon-expandable stent system for the treatment of atherosclerotic peripheral arterial disease (PAD) lesions in the iliac arteries. The study…
‘Proceed cautiously in use of DCBs in CLTI patients with advanced WIfI stage’
The last several years have seen ongoing controversy and debate about the risks and benefits of paclitaxel-coated devices (PCDs) for patients with peripheral arterial disease (PAD). The latest contribution from Konstantinos Katsanos, MD, and colleagues raises questions about potential increased…
European launch: Medtronic receives CE mark for 200mm and 250mm IN.PACT Admiral DCBs
Medtronic has announced the European launch of the 200mm and 250mm IN.PACT Admiral drug-coated balloons (DCBs) following CE mark approval. The product is intended to treat long complex femoropopliteal lesions efficiently in patients with peripheral arterial disease (PAD). The 200mm and 250mm IN.PACT Admiral…
PAD: R3 Vascular reports ‘successful initiation’ of first-in-human study of bioresorbable sirolimus-eluting scaffold
Medical device developer R3 Vascular has reported the “successful initiation” of a first-in-human clinical study evaluating the technical and clinical performance of its Magnitude bioresorbable sirolimus-eluting scaffold (BRS) in patients with critical limb ischemia (CLI) due to occlusive below-the-knee (BTK)…
Physicians draw attention to Medicare cuts as PAD Awareness Month kicks off
A coalition of physicians and other interested parties focused on peripheral arterial disease (PAD) has called on Congress and the Centers for Medicare and Medicaid Services (CMS) to take action to avoid proposed payment cuts that would hammer vascular care,…
Females were 30% less likely to undergo surgery for PAD, national database study finds
A review of more than 1 million patients receiving vascular surgery over a 16-year period identified significant sex-related disparities in the treatment of abdominal aortic aneurysms (AAAs) and peripheral arterial disease (PAD)—with females 30% less likely to undergo surgery in…
USPSTF expands screening recommendation for prediabetes, type-2 diabetes to adults aged 35-plus
The United States Preventive Services Task Force (USPSTF) has issued an updated recommendation statement suggesting clinicians screen for prediabetes and type-2 diabetes in overweight or obese adults aged 35–70 years—capturing patients five years earlier than the previous advisory from 2015.…